A Phase 2, Randomized, Double-Blind, Placebo-Controlled, 12-Week Dose-Ranging Study to Assess the Efficacy and Safety of Etrasimod in Japanese Participants With Moderately to Severely Active Ulcerative Colitis
Latest Information Update: 04 Dec 2023
At a glance
- Drugs Etrasimod (Primary)
- Indications Ulcerative colitis
- Focus Therapeutic Use
- Sponsors Pfizer
- 27 Nov 2023 Status changed from active, no longer recruiting to completed.
- 05 Jul 2023 Status changed from recruiting to active, no longer recruiting.
- 10 Feb 2023 Planned End Date changed from 31 Dec 2023 to 1 Dec 2023.